Skip to main content
. 2023 Jul 6;24(8):e56525. doi: 10.15252/embr.202256525

Figure 9. Human recombinant EN1 injection at 1 month prevents p62/SQSTM1 overexpression and strength loss in 3‐month‐old En1‐Het mice.

Figure 9

  1. Left panel: Injection and analysis protocol. Right panel: muscle strength analysis demonstrating that hEN1 injection at 1 month prevents muscular strength decrease observed in 3‐month‐old En1‐Het mice. One‐way ANOVA followed by two‐sided t‐test. (*P < 0.05, ****P < 0.0001). N = 6–10. Data information: This experiment was performed once. Values are mean ± SD.
  2. Left panel: Increased p62/SQSTM1 staining in 3‐month‐old ChAT+ MNs from control En1‐Het is abolished by hEN1 injection at 1 month. Right panel: quantification of p62/SQSTM1 staining in γMNs and αMNs of control and hEN1‐injected 3‐month‐old En1‐het mice. One‐way ANOVA followed by two‐sided t‐test. (**P < 0.01, ****P < 0.0001).

Data information: This experiment was performed once. Values are mean ± SD. Between 111 and 303 neurons and 4–5 mice were analyzed for each condition.

Source data are available online for this figure.